Ionis Pharmaceuticals Inc... (IONS)
The price, the headline numbers and the latest news, in one place.
Ionis Pharmaceuticals Inc. (IONS) Stock Price, Analysis & Data
| Bid | 56.26 |
| Market Cap | 10B |
| Revenue (ttm) | 874.09M |
| Net Income (ttm) | -565.17M |
| 0.40 | |
| -3.48 | |
| n/a | |
| -57.07 | |
| P/B (ttm) | 22.67 |
| P/S (ttm) | 11.44 |
| Earnings Date | Nov 4, 2026 |
| Ask | 61 |
| Volume | 1,850,625 |
| Avg. Volume (20D) | 2,955,180 |
| Open | 60.62 |
| Previous Close | 62.43 |
| Day's Range | 60.35 - 61.69 |
| 52-Week Range | 49.13 - 86.74 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) i...
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was 943.71M, an increase of 33.83% compared to the previous year's 705.14M. Earnings were -381.39M, a decrease of -15.97%.
Financial StatementsEarnings Surprise
- Revenue of $267.95M misses estimates by $0, with -40.73% YoY decline.
- EPS of -0.42 exceeds estimates by 0.46, with -149.41% YoY decline.
Analysts project revenue of ... Upgrade
2 weeks ago · Simply Wall St.
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On SalesIonis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares trading at a premium rather than as a...
